Advanced search
Publication Cover
Future Oncology Volume 19, 2023 - Issue 1
Submit an article Journal homepage
1,548
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA

Jay M Lee1 David Geffen School of Medicine at UCLA,Los Angeles,CA90095, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3715-6749View further author information
ORCID Icon,
Rongrong Wang2 Genentech, Inc.,South San Francisco,CA94080,USAView further author information
,
Ann Johnson2 Genentech, Inc.,South San Francisco,CA94080,USAView further author information
,
Sarika Ogale2 Genentech, Inc.,South San Francisco,CA94080,USAView further author information
,
Matthew Kent3 Genesis Research,Hoboken,NJ07030,USAView further author information
&
Janet S Lee2 Genentech, Inc.,South San Francisco,CA94080,USAView further author information
Pages 37-47 | Received 23 Aug 2022, Accepted 20 Dec 2022, Published online: 20 Jan 2023

References

  • Howlader N , KrapchoM, MillerDet al. SEER Cancer Statistics Review, 1975–2016. National Cancer Institute, MD, USA (2020).
  • Lu T , YangX, HuangYet al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag. Res.11, 943–953 (2019).
  • Goldstraw P , ChanskyK, CrowleyJet al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J. Thorac. Oncol.11, 39–51 (2016).
  • Howlader N , ForjazG, MooradianMJet al. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med.383, 640–649 (2020).
  • Pisters K , KrisMG, GasparLEet al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I–IIIA completely resected non-small-cell lung cancer: ASCO guideline rapid recommendation update. J. Clin. Oncol.40, 1127–1129 (2022).
  • Pignon J-P , TribodetH, ScagliottiGVet al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol.26, 3552–3559 (2008).
  • NSCLC Meta-analysis Collaborative Group . Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet383, 1561–1571 (2014).
  • Martin J , GinsbergRJ, VenkatramanESet al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J. Clin. Oncol.20, 1989–1995 (2002).
  • Uramoto H , TanakaF. Recurrence after surgery in patients with NSCLC. Transl. Lung Cancer Res.3, 242–249 (2014).
  • Sugimura H , NicholsFC, YangPet al. Survival after recurrent non small-cell lung cancer after complete pulmonary resection. Ann. Thorac. Surg.83, 409–417 (2007).
  • MacLean M , LuoX, WangS, KernstineK, GerberDE, XieY. Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database. Oncotarget9, 24470–24479 (2018).
  • Felip E , AltorkiN, ZhouCet al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet398, 1344–1357 (2021).
  • Wu Y-L , TsuboiM, HeJet al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med.383, 1711–1723 (2020).
  • Enewold L , ParsonsH, ZhaoLet al. Updated overview of the SEER-Medicare data: enhanced content and applications. J. Natl Cancer Inst. Monogr.2020(55), 3–13 (2020).
  • Nadpara P , MadhavanSS, TworekC. Guideline-concordant timely lung cancer care and prognosis among elderly patients in the United States: a population-based study. Cancer Epidemiol.39, 1136–1144 (2015).
  • Goldstraw P , CrowleyJ, ChanskyKet al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol.2, 706–714 (2007).
  • Quan H , LiB, CourisCMet al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol.173, 676–682 (2011).
  • Salazar MC , RosenJE, WangZet al. Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA Oncol.3, 610–619 (2017).
  • Wang B-Y , HuangJ-Y, HungW-Het al. Impact on survival on interval between surgery and adjuvant chemotherapy in completely resected stage IB–IIIA lung cancer. PLOS ONE11, e0163809 (2016).
  • Altorki N , FelipE, ZhouCet al. IMpower010: characterization of stage IB–IIIA NSCLC patients by type and extent of therapy prior to adjuvant atezolizumab. Oral presentation at: World Conference on Lung Cancer.Virtual (September 2021).
  • Früh M , RollandE, PignonJ-Pet al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J. Clin. Oncol.26, 3573–3581 (2008).
  • Morgansztern D , SamsonPS, WaqarSNet al. Early mortality in patients undergoing adjuvant chemotherapy for non-small cell lung cancer. J. Thorac. Oncol.13, 543–549 (2018).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.